Generics Firms Culled In Germany As Discount Contracts Bite
This article was originally published in The Pink Sheet Daily
Germany’s discount contracts have secured huge savings for health insurers and the government, but are forcing generics manufacturers to reduce portfolios or leave the market altogether.
You may also be interested in...
Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven
EGA Director General Adrian van den Hoven will call on the new European Commission and Parliament to introduce efficiency policies to increase the uptake of and access to generic drugs and biosimilars.
The new German drug register is designed to be a first step in tackling potential drug shortages on the domestic market, but it currently lacks effective solutions.
Germany's largest insurer AOK has announced the winners of its two-year, price-driven generic supply contracts, but court appeals by disgruntled losers threaten the system.